A physician makes a decision at the patient's bedside — not at a meeting with a medical representative. We help your drug become part of that decision.
Physicians are overloaded with information, do not trust overtly promotional materials, and expect useful content that helps in real practice. Our task is not just to "sell," but to address the physician's medical need, giving them a tool for reflection and decision-making.
Brings together experts with experience in clinical studies, biostatistics, evidence-based medicine, and medical marketing. We help pharmaceutical companies create independent, scientifically grounded materials useful to physicians that build loyalty and trust in the drug.
The data is obtained on "refined" patients, often without additional severe comorbidities and polypharmacy.
They need independent expert appraisal, clinical case reviews, and practical algorithms.
Without it, it is difficult to substantiate efficacy in a broad population in Russia.
Physicians ignore standard medical-representative materials — brochures and slide sets. Formats the physician chooses themselves are needed: video, cases, interactive content.
This works because we don't write "our drug is the best." We show the physician: "Here is the problem, here is the data, here is the solution — and here is the evidence." The physician draws their own conclusion.
Clinical cases
Videos with experts, reviews of real patients, and interactive formats for Telegram bots and other digital channels.
Slide sets
A physician trusts the material when they reach the conclusion themselves. We build the logic: problem → data → the drug's place in practice
Publications
Narrative reviews, systematic reviews, meta-analyses, and articles based on study results.
Approved letters and materials for medical representatives
Adapted for different audiences (GPs, internists, surgeons, and specialists).
Content strategies for entering new therapeutic niches
Analysis of the evidence base, identification of unmet medical needs, and positioning.
Legal compliance
All materials rely solely on the approved label, the regulatory acts of Russia, and the AIPM Code.
Webinars on doclub.tv
Access to a base of > 69,000 physicians, an events calendar, banner support, and an AI assistant for answering questions.
Symposia within specialized forums
Cardiology, internal medicine, neurology, and others.
Expert councils and round tables
With the participation of opinion leaders. Not "talking heads," but real practitioners.
Registration of studies on clinicalstudy.ru
Obtaining an official registry number (the Russian equivalent of ClinicalTrials.gov).
Prospective and retrospective medical registries, turnkey
Protocol, documentation, and data quality control.
Real-world practice analysis
Demonstration of the efficacy and safety of the drug in broad (comorbid) populations.
Publications based on registry results in peer-reviewed journals
Development of a scientific and regulatory strategy
Originator and generic drugs.
Preparation of documentation for clinical studies
Protocols, investigator's brochures, and informed consent forms.
Responses to regulator inquiries
Including the EAEU — we engage experts as needed.
We understand your drug, audience, and medical needs.
For the study or content project.
On clinicalstudy.ru when needed
With a focus on benefit to the physician.
We bring it to the target audience
real cases
the russian equivalent of clinicaltrials.gov
All medical registries and studies we run for pharmaceutical companies receive official public status and a registration number on the clinicalstudy.ru platform. A registered study is not just a number. It is public confirmation of the independence of your data, visible to regulators, journals, and investigators.
Regulators and the scientific community see that the study is openly registered — this increases trust in the data.
A public registry is an additional channel for engaging investigators.
Strengthening the evidence base through transparency.